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A 
 
PEPTIDE inhibiting the release of growth hor-
mone was originally detected accidentally during
studies of the distribution of growth hormone–releasing
factor in the hypothalamus of rats.
 
1
 
 This peptide, called
somatostatin, proved to be a cyclic peptide consisting
of 14 amino acids.
 
2
 
 Subsequent work has considerably
expanded this initially simple concept of somatostatin
as a peptide whose main function is the regulation of
growth hormone secretion.
 
3
 
 Today, somatostatin is best
regarded as a phylogenetically ancient, multigene fam-
ily of peptides with two important bioactive products:
somatostatin-14 and somatostatin-28, the latter a con-
gener of somatostatin-14 extended at the N-terminal.
 
3,4
 
 
Like other peptide hormones, somatostatin is synthe-
sized as part of a large precursor molecule that is rap-
idly cleaved into the prohormone form and processed
enzymatically to yield several mature products.
 
3,4
 
 So-
matostatin modulates neurotransmission in the central
nervous system (as a neurotransmitter) and regulates
the release of growth hormone and thyrotropin (as a
neurohormone). It also has a regulatory role in the gas-
trointestinal tract, as well as in the exocrine and endo-
crine pancreas. When synthesized and released by en-
docrine and nerve cells in the gastrointestinal tract and
pancreas, somatostatin acts in an autocrine, paracrine,
or neuronal regulatory manner to inhibit glandular se-
cretion, neurotransmission, smooth-muscle contractility,
and absorption of nutrients.
 
3,4
 
 It also inhibits the func-
tion of activated immune cells.
 
5
 
 
 
S
 
OMATOSTATIN
 
 R
 
ECEPTORS
 
The various actions of somatostatin are mediated
through specific membrane receptors, which have been
demonstrated in various regions of the brain and lep-
tomeninges, the anterior pituitary, the endocrine and
exocrine pancreas, and the mucosa of the gastrointes-
tinal tract, as well as in cells of the immune system.
 
6,7
 
Five subtypes of the human somatostatin receptor have
been cloned and characterized (Table 1). These subtypes,
which are identical in 42 to 60 percent of their amino
acid sequences, belong to a superfamily of receptors
with seven membrane-spanning domains (Fig. 1A).
 
8-11
 
The genes for these subtypes are located on different
chromosomes, suggesting different functions in different
organs (Table 1). Indeed, distinct but often overlapping
patterns in the expression of these subtypes have been
demonstrated. All five subtypes are functionally linked to
adenylate cyclase through a coupling mechanism involv-
ing guanine nucleotide–binding (G) protein (Fig. 1).
 
21-23
 
Somatostatin-mediated activation of potassium chan-
nels and inhibition of voltage-dependent calcium chan-
nels are signal-transduction mechanisms that are re-
versed by pertussis toxin, although these two processes
have not yet been demonstrated to be coupled to spe-
cific subtypes of somatostatin receptors.
 
24
 
 In the brain,
somatostatin activates phospholipase C and phospholip-
ase A and mobilizes calcium.
 
25
 
 Activation of somatostat-
in-receptor subtype 1 and subtype 2 results in the activa-
tion of tyrosine phosphatase, which is related to the
antimitotic effects of somatostatin in some types of
cells.
 
20,26
 
 In addition, inhibition of cell proliferation is me-
diated by somatostatin-receptor subtype 5, but through a
different mechanism, probably involving changes in in-
tracellular calcium mobilization.
 
27
 
 
 
S
 
OMATOSTATIN
 
 A
 
NALOGUES
 
Because of its ability to inhibit many functions of var-
ious organs, the expectation was that somatostatin
would be of therapeutic value in clinical conditions in-
volving the hyperfunction of these organs.
 
28
 
 Clinical use
of somatostatin was hampered, however, by the need for
intravenous administration, its short duration of action
(a half-life in the circulation of less than three minutes),
and the postinfusion rebound hypersecretion of hor-
mones, such as growth hormone, insulin, and gluca-
gon.
 
28
 
 Attempts have been made to synthesize somato-
statin analogues that do not have these disadvantages.
Octreotide, the first somatostatin analogue introduced
for clinical use, inhibits the release of growth hormone,
glucagon, and insulin in monkeys 45, 11, and 1.3 times
more powerfully, respectively, than somatostatin-14.
 
29
 
Its elimination half-life after subcutaneous administra-
tion is two hours, and rebound hypersecretion of hor-
mones does not occur.
 
30,31
 
 Two other cyclic analogues
with slightly different activity profiles, vapreotide (RC-
160) and lanreotide (BIM-23014),
 
20,32
 
 are being tested
in clinical trials in Europe.
All five somatostatin-receptor subtypes bind somato-
statin-14 and somatostatin-28 with a similar high affin-
ity, but there are differences in the binding affinities of
the structural analogues of somatostatin (Table 1).
 
12-14,23
 
Octreotide binds with a high affinity to somatostatin-
receptor subtype 2 and subtype 5 and with a moderate
affinity to subtype 3 but does not bind to subtypes 1 and
4. The binding characteristics of vapreotide and lan-
reotide are only slightly different, except with regard to
subtype 4 (Table 1). Cyclic somatostatin analogues such
as octreotide are more potent inhibitors of the release
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of growth hormone than of the release of insulin,
 
29
 
because the inhibition of growth hormone and insulin
secretion is mediated by different somatostatin-recep-
tor subtypes.
 
33
 
 
We review the established indications for the use of
somatostatin analogues in the treatment of various dis-
eases and consider the potential use of these analogues
for other disorders.
 
T
 
REATMENT
 
 
 
OF
 
 H
 
ORMONE
 
-S
 
ECRETING
 
 T
 
UMORS
 
Acromegaly
 
Most tumors originating from somatostatin target tis-
sues have a high density of somatostatin receptors. This
observation was first made with growth hormone–secret-
ing pituitary tumors, most of which have a large number
of receptors for somatostatin analogues.
 
34
 
 The presence
of these receptors is required for the successful use of oc-
treotide to control hormone secretion in patients with
growth hormone–secreting pituitary tumors. The short-
term suppression of growth hormone in response to oc-
treotide in a patient with acromegaly depends on the
number of octreotide receptors on the pituitary tumor,
 
34
 
and this early effect predicts the ultimate effect of long-
term therapy on serum growth hormone and insulin-like
growth factor I concentrations.
 
35,36
 
 
The usual initial dose of octreotide is three daily sub-
cutaneous injections of 100 
 
m
 
g each. Both the number of
injections and the dose, however, can be increased to
achieve the maximal benefit.
 
37
 
 Among patients receiv-
ing 300 to 600 
 
m
 
g of octreotide daily, up to 90 percent
have suppressed serum growth hormone concentrations,
over half have serum growth hormone concentrations
of less than 5 
 
m
 
g per liter, and about 70 percent have
normal serum insulin-like growth factor I concentra-
tions.
 
36-38
 
 A dose above 600 
 
m
 
g per day rarely has ad-
ditional effects.
 
37,38
 
 Overall, in comparative studies in a
group of patients with acromegaly, octreotide was more
effective than bromocriptine
 
39
 
; some patients have a bet-
ter response to the combination of octreotide and bro-
mocriptine than to either drug alone.
 
40
 
 The size of the
tumor is reduced in about half the patients treated
with octreotide.
 
35,37,38
 
 The mechanism of tumor shrink-
age is probably a (reversible) decrease in the size of in-
dividual tumor cells.
 
38
 
 
Octreotide is particularly effective in reducing the
headaches that are often associated with acromegaly,
an effect that may be mediated by opioid receptors.
 
38
 
Other symptoms of acromegaly, including joint pain,
excessive perspiration, cardiomyopathy, and sleep ap-
nea, are reduced or eliminated in most patients, and in
many patients, the subjective clinical benefits of octre-
otide therapy are greater than the decreases in serum
growth hormone and insulin-like growth factor I concen-
trations. Octreotide may also directly decrease growth
hormone–stimulated production of insulin-like growth
factor I. Increased serum prolactin concentrations, as
well as galactorrhea or (secondary) amenorrhea, often
resolve during treatment with octreotide in patients
with acromegaly who have pituitary adenomas secret-
ing both growth hormone and prolactin.
 
41
 
 
Thus, octreotide is a rapidly acting and effective ther-
apy for the majority of patients with acromegaly. Pa-
tients who have undergone an unsuccessful transsphe-
noidal operation or are awaiting the therapeutic effect
of external pituitary irradiation are candidates for treat-
ment with octreotide. Because growth hormone–secret-
ing tumors in elderly patients are also highly sensitive
to octreotide, it can be recommended as a primary treat-
ment for such patients.
 
42,43
 
 
The benefits of octreotide in the treatment of pa-
tients with acromegaly must be weighed against its ad-
verse effects (discussed below). There have been no re-
ports of the loss of the suppressive effect of octreotide
on growth hormone secretion in patients with acro-
megaly, even after more than 10 years of uninterrupted
therapy.
 
38,43
 
 The high cost of treatment with octreotide
 
*Data on the five subtypes were obtained from the following reports: subtypes 1 and 2, Yamada et al.
 
8
 
; subtype 3, Yamada et al.
 
9
 
; subtype 4, Bruno et al.
 
10
 
; and subtype 5, O’Carroll et al.
 
11
 
†IC
 
50
 
 denotes the concentration required for 50 percent inhibition of the binding of 
 
125
 
I-labeled somatostatin to the cloned subtype, as expressed in Chinese hamster-ovary or transformed
African green-monkey COS kidney cells. Data were obtained from Patel and Srikant.
 
12
 
‡The value is reported as 4.4 nM by Patel and Srikant,
 
12
 
 31.6 nM by Bruns et al.,
 
13
 
 and 35 nM by Kubota et al.
 
14
 
§Not all human tissues have been tested simultaneously. Data were obtained from Yamada et al.,
 
8
 
 Kaupmann et al.,
 
15
 
 Rohrer et al.,
 
16
 
 Panetta et al.,
 
17
 
 O’Carroll et al.,
 
18
 
 and Bell and Reisine.
 
19
 
Table 1. Properties of the Five Cloned Subtypes of Human Somatostatin Receptors.
 
*
 
P
 
ROPERTY
 
S
 
OMATOSTATIN
 
 R
 
ECEPTOR
SUBTYPE
 
 1
 
SUBTYPE
 
 2
 
SUBTYPE
 
 3
 
SUBTYPE
 
 4
 
SUBTYPE
 
 5
 
Chromosomal location 14 17 22 20 16
G protein coupling Yes Yes Yes Yes Yes
Effector system
Adenylate cyclase activity
Tyrosine phosphatase activity
Reduced
Increased
Reduced
Increased
Reduced
Not investigated
Reduced
Not investigated
Reduced
Not investigated
IC
 
50
 
 (nM)†
Somatostatin-14
Somatostatin-28
Octreotide
Vapreotide (RC-160)
Lanreotide (BIM-23014) 
1.1
2.2
 

 
1000
 

 
1000
 

 
1000
1.3
4.1
2.1
5.4
1.8
1.6
6.1
4.4–35‡
30.9
43.0
0.5
1.1
 

 
1000
45.0
66.0
0.9
0.07
5.6
0.7
0.6
Distribution in normal 
human tissue§
Brain, lungs, stomach, jejunum, 
kidneys, liver, and pancreas
Brain and kidneys Brain and pancreas Brain and lungs Brain, heart, adrenal glands, pla-
centa, pituitary, small intestine, 
and skeletal muscle
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(about $7,800 annually for a daily dose of 300 
 
m
 
g) must
also be considered.
 
Thyrotropin-Secreting Pituitary Adenomas
 
Most thyrotropin-secreting pituitary adenomas ex-
press somatostatin receptors.
 
44
 
 In a group of 33 patients
with this type of tumor, 30 (91 percent) had a response
to short-term treatment with octreotide (100 to 300 
 
m
 
g
daily), with a decrease in thyrotropin secretion, and se-
rum thyroxine concentrations declined to normal val-
ues in 73 percent of the patients.
 
44
 
 
 
Nonsecretory Pituitary Adenomas
 
Most nonsecretory pituitary tumors express somato-
statin receptors.
 
45
 
 Therapy with octreotide seldom re-
sults in a reduction in the size of the tumor, but 30 to
40 percent of patients have improvement in visual-field
defects within days after the initiation of treatment.
 
46
 
This response may reflect a direct effect of octreotide
on the retina or optic nerve. These studies have been
carried out with doses of octreotide ranging from 300
to 1500 
 
m
 
g per day, and no particular dose can be rec-
ommended at present.
 
Corticotropin-Secreting Pituitary Adenomas
 
No somatostatin receptors have been found on corti-
cotropin-secreting pituitary adenomas in patients with
Cushing’s disease.
 
38
 
 However, most other tumors that
secrete corticotropin, such as bronchial and thymic car-
cinoids, pancreatic islet-cell tumors, and medullary thy-
roid carcinomas, express somatostatin receptors, and
octreotide controls hormonal secretion in some patients
with these tumors.
 
38,47
 
 
 
Pancreatic Islet-Cell Tumors
 
Pancreatic islet-cell tumors retain characteristics of
the cells from which they originate, and more than 80
percent of these tumors express somatostatin receptors.
 
6
 
Most are slowly growing malignant tumors that have
 
Figure 1. Model of the Effector Systems Coupled to Somatostat-
in Receptors.
Panel A shows a general model of a receptor coupled to G pro-
tein. Somatostatin receptors belong to this superfamily of recep-
tors with seven membrane-spanning domains. The Greek letters
denote the protein subunits. Panel B shows the coupling of the
somatostatin receptor (SSTR) to adenylate cyclase (ACL). Acti-
vation of the receptor may result in a reduction (minus sign) in
intracellular cyclic AMP (cAMP) concentrations through the inhi-
bition (minus sign) of adenylate cyclase. SST denotes somato-
statin, and G
 
i 
 
inhibitory G protein. Panel C shows the coupling
of the somatostatin receptor to ion channels. Activation of the
receptor may result in a decrease in the influx of calcium (Ca
 
2
 

 
),
either directly through the inhibition of calcium channels or indi-
rectly through a stimulatory effect (plus sign) on the efflux of po-
tassium (K
 

 
). G
 
o
 
 and G
 
k
 
 denote G
 
o
 
 protein and G
 
k
 
 protein, re-
spectively. Panel D shows the coupling of the somatostatin
receptor to tyrosine phosphatase. Activation of the receptor may
result in the stimulation (plus sign) of tyrosine phosphatase ac-
tivity. This effect is thought to be involved in the antimitotic ac-
tions of somatostatin and its analogues by reversing epidermal
growth factor (EGF)–induced phosphorylation of EGF-receptor
(EGFR) tyrosine kinase (dashed arrow).
 
20
 
 G denotes G protein.
K
A
Receptor
N-terminal
G protein
Extracellular
Plasma
membrane
Intracellular

 
B
ATP cAMP↓
Gi
SSTR
SST
ACL

SSTR
SST
Go
Decrease in action
potential due to
hyperpolarization
C
SSTR
SST
Tyrosine
phosphatase
Inhibition of
EGF-receptor
autophosphorylation
D
G
Decrease in influx
of Ca2
Gk




EGFR
EGF
K
K
Ca2
Ca2
Ca2
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metastasized at the time of diagnosis, but their clinical
manifestations are largely related to hormonal hyperse-
cretion. Treatment with octreotide ameliorates many of
the clinical problems — for example, diarrhea, dehydra-
tion, and hypokalemia in patients with tumors secreting
vasoactive intestinal polypeptide and peptic ulceration,
hypoglycemic attacks, and necrolytic skin lesions in pa-
tients with tumors secreting gastrin, insulin, and gluca-
gon, respectively.
 
48,49
 
 Clinical improvement occurs in 50
to 85 percent of patients during treatment with 150 to
300 
 
m
 
g of octreotide per day and is mediated both by a
direct inhibitory effect on hormone production by the
tumor and by indirect effects — for example, on the re-
sorption of intestinal fluid, the production of hydrochlo-
ric acid, or intestinal contractility.
 
48,49
 
 
Octreotide is especially valuable in the control of
symptoms associated with vipomas or glucagonomas.
There is little or no effect on tumor growth, however,
and after weeks to months of treatment with octreotide,
symptoms worsen and hormone secretion by the tumor
increases in virtually all patients.
 
50
 
 This effect can ini-
tially be reversed by increasing the dose of octreotide,
but eventually the drug is ineffective in all patients. The
loss of sensitivity of endocrine cancers to octreotide is
probably associated with the growth of clones of tumor
cells that lack somatostatin receptors rather than with
a transient down-regulation of these receptors.
 
28,51
 
 In pa-
tients with gastrinomas, symptoms can often be con-
trolled with histamine H
 
2
 
-receptor–blocking drugs or
proton-pump inhibitors. Most insulinomas express so-
matostatin-14 and somatostatin-28 receptors, but in
about 50 percent of patients, these tumors express recep-
tor subtypes that do not bind octreotide.
 
31
 
 
 
Carcinoid Tumors
 
As with growth hormone–secreting pituitary adeno-
mas, the number of somatostatin receptors on carcinoid
tumors determines the suppressive effect of long-term
octreotide therapy on hormonal hypersecretion by the
tumors.
 
52
 
 Control of the symptoms, such as diarrhea
and flushing attacks, caused by an overproduction of se-
rotonin or tachykinin has been reported in 70 to 90 per-
cent of patients with metastatic carcinoid tumors.53 Oc-
treotide may also temporarily inhibit tumor growth, and
in about 20 percent of patients, enlarged lymph nodes
and liver metastases shrink.53 Most important, however,
is the improvement in the quality of life during octreo-
tide therapy, and preliminary evidence suggests that such
therapy may prolong survival.54 
GASTROINTESTINAL INDICATIONS
Since natural somatostatin inhibits a wide variety of
physiologic regulatory functions in the gastrointestinal
tract, as well as in the exocrine and endocrine pancreas
(Fig. 2),3,55 somatostatin and its analogues have been
viewed as potentially useful in patients with a number
of gastrointestinal and pancreatic diseases. For exam-
ple, the physiologic actions of somatostatin suggest that
Figure 2. Gastrointestinal Actions of Natural Somatostatin-14. 
Data were obtained from Reichlin3 and Harris.55 
Reduces liver
blood flow
Inhibits gallbladder
contractility and bile flow
Inhibits gastrointestinal and
pancreatic peptide hormone
secretion
Inhibits gastric acid and
pepsin secretion
Inhibits pancreatic exocrine
secretion
Slows gastrointestinal transit
time and inhibits absorption
of glucose and amino acids
Reduces splanchnic
blood flow
Stimulates water and
electrolytic absorption
Inhibits tissue growth and
proliferation
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its analogues might help control bleeding from a peptic
ulcer. In a five-day, double-blind, placebo-controlled tri-
al involving 273 patients, however, there was no differ-
ence in the rates of controlled bleeding in the placebo
and octreotide groups (71 and 70 percent, respectively).56
The rates of surgery and the requirements for blood
transfusion were also not influenced by the use of octre-
otide.56 These results indicate that somatostatin and its
analogues are not effective in the treatment of bleeding
from a peptic ulcer.
The use of a somatostatin analogue has been benefi-
cial, however, in the control of bleeding from esophage-
al varices.57,58 In a study of 100 patients, the effect of in-
jection sclerotherapy in the treatment of acute variceal
hemorrhage was compared with that of octreotide (50 mg
given as an intravenous bolus dose followed by a con-
tinuous infusion of 50 mg per hour for 48 hours).59 At
the end of the 48-hour study period, the patients receiv-
ing octreotide also received sclerotherapy to obliterate
the varices.59 Octreotide therapy and emergency scler-
otherapy were equally effective in the acute control of
variceal bleeding. This study suggests that octreotide can
be administered when injection sclerotherapy is not avail-
able and is probably also useful for recurrent bleeding
after sclerotherapy.
Somatostatin inhibits exocrine pancreatic secretion.3,55
Somatostatin analogues might therefore be expected to
be of benefit in disorders in which the pancreatic-duct
flow is compromised. In four placebo-controlled trials
involving nearly 400 patients, however, neither natural
somatostatin nor octreotide improved the course of acute
pancreatitis.60 Octreotide also did not prevent pain or
pancreatitis after endoscopic retrograde cholangiopan-
creatography.61 
Octreotide has been administered to reduce fluid pro-
duction by pancreatic fistulas and pseudocysts. A re-
view of 26 reports on octreotide therapy (100 to 450 mg
per day) in 68 patients with pancreatic fistulas revealed
a considerable reduction in fluid production in virtual-
ly all patients,55 but it remains uncertain whether octre-
otide, as compared with surgical intervention and total
parenteral nutrition, results in a larger number of closed
fistulas or in earlier closure. In two placebo-controlled
studies involving nearly 500 patients undergoing elec-
tive pancreatic surgery, the patients receiving octreo-
tide (100 mg three times a day for seven days perioper-
atively) had significantly lower rates of postoperative
complications than the patients receiving placebo.62,63 
Somatostatin prolongs the gastrointestinal transit time,
decreases endogenous fluid secretion in the jejunum,
and stimulates intestinal absorption of water and elec-
trolytes.3,55 Both somatostatin and octreotide (50 to 500
mg per day) improve secretory diarrhea in patients with
ileostomies, the short-bowel syndrome, intestinal graft-
versus-host disease, radiation colitis, or intestinal fistu-
las.55 Patients with the acquired immunodeficiency syn-
drome (AIDS) may have high-volume watery diarrhea,
and in about half these patients enteropathogens such
as cryptosporidium can be identified. In two prospec-
tive open-label trials involving 110 patients with AIDS-
related diarrhea, a dose of 150 to 1500 mg per day for
14 days, a dose determined on the basis of stool volume,
induced a complete response in 19 percent of the pa-
tients and a partial response, with a 50 percent reduc-
tion in stool volume, in 27 percent55,64; the patients with
responses also had an improved quality of life. In most
studies of patients with AIDS and high-volume secreto-
ry diarrhea, however, there has been a tendency for di-
arrhea to recur despite continued treatment with octre-
otide.
POTENTIAL ROLE IN ONCOLOGIC TREATMENT
Somatostatin analogues inhibit the growth of a vari-
ety of tumors in animals.31,65 This action may occur as
a result of inhibition of the secretion of growth hor-
mone, insulin, and gastrointestinal hormones; direct or
indirect (through growth hormone) inhibition of the
production of insulin-like growth factor I or its binding
proteins; direct inhibition of angiogenesis; or direct an-
tiproliferative effects on tumor cells, mediated by soma-
tostatin receptors.
Like most neuroendocrine tumors, adenocarcinomas
originating in the breast, kidney, colon, or ovary, as well
as meningiomas, express somatostatin receptors.6,31 De-
spite the direct antimitotic effects of somatostatin ana-
logues on some human cancer cell lines positive for so-
matostatin receptors,31 the heterogeneous distribution of
somatostatin receptors in many adenocarcinomas sug-
gests that treatment with these analogues will affect
only some areas of the tumors,6,31 and a role for treat-
ment with a somatostatin analogue in patients with in-
operable somatostatin-receptor–positive adenocarcino-
mas has not been established.31 The high density of
somatostatin receptors on some tumors, as well as the
availability of potent and stable somatostatin analogues
as radioligands, has made it possible to use somatostat-
in-receptor scintigraphy with 111In-labeled pentetic acid–
D-Phe1-octreotide for the visualization of somatostatin-
receptor–positive cancers.31,66 
More information about the expression of different
subtypes of somatostatin receptors in different cancers
should soon be available. As mentioned above, one sub-
type may be linked to more than one effector system
(Table 1 and Fig. 1), and the stimulation of tyrosine phos-
phatase activity by somatostatin analogues may be
linked preferentially to an antimitotic effect.20,26 In this
respect the differential antihormonal and antimitotic
effects of somatostatin-14, octreotide, and lanreotide
seem important.20,26,65,67 A limited number of studies
have demonstrated heterogeneous expression of the
various somatostatin-receptor subtypes on human tu-
mors, such as pituitary adenomas,68,69 islet-cell tumors,
and carcinoids.14,70 Further developments in the use of
somatostatin analogues in patients with these tumors
await the definitive identification of the receptor sub-
type (or subtypes) mediating the antiproliferative ef-
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fects of somatostatin, as well as the development of one
or more analogues that selectively activate the receptor
subtype (or subtypes).
ADVERSE EFFECTS OF OCTREOTIDE
Common adverse effects of treatment with octreo-
tide include nausea, abdominal cramps, diarrhea, mal-
absorption of fat, and flatulence.38,43,55 These symptoms
start within hours after the first injection of the drug,
their severity is dose-dependent, and they usually
subside spontaneously in 10 to 14 days, despite contin-
ued treatment. The occurrence of these adverse ef-
fects can be readily understood from the physiologic
actions of somatostatin on the gastrointestinal tract
and exocrine pancreas, as shown in Figure 2. The spon-
taneous resolution of these symptoms supports the con-
cept of a rapid adaptation to the effects of somato-
statin on the function of the gastrointestinal tract and
pancreas.
Since somatostatin analogues inhibit the secretion of
insulin, reduced glucose tolerance and even overt hyper-
glycemia might be expected during therapy with oc-
treotide.38,43 Although the drug has a short-lived inhib-
itory effect on insulin secretion, its ability to delay the
absorption of carbohydrates and inhibit the secretion of
growth hormone and glucagon prevents a clinically im-
portant effect on carbohydrate metabolism during long-
term therapy.36,38,43 
Long-term treatment with octreotide (1 month) is
associated with an increased incidence of cholesterol
gallstones (occurring in approximately 20 to 30 per-
cent of patients).43 The prevalence of octreotide-induced
gallstones varies geographically and may be influenced
by dietary, environmental, or racial factors.71 The for-
mation of gallstones during octreotide therapy proba-
bly involves inhibition of gallbladder emptying and in-
testinal motility, inhibition of the secretion of prokinetic
peptides such as cholecystokinin, and increased intes-
tinal and biliary production of deoxycholic acid, all of
which promote the nucleation of cholesterol crystals
and their aggregation into stones.71 Because of poor
gallbladder emptying, crystals and small stones are
not discharged after meals. Fortunately, in most cases
the gallstones remain asymptomatic: only approximately
1 percent of patients have symptoms per year of treat-
ment.43 
NEW FORMS OF SOMATOSTATIN ANALOGUES
Octreotide has to be administered subcutaneously two
or three times daily. A long-acting form that has recent-
ly been developed consists of 20 to 30 mg of octreo-
tide mixed with microspheres of DL-lactide-co-glycolide
polymer.72 In most patients with acromegaly, an intra-
muscular injection of this preparation controls growth
hormone hypersecretion for 28 to 42 days as effectively
as do multiple daily subcutaneous injections (Fig. 3).
A long-acting intramuscular formulation of lanreotide
also controls growth hormone secretion in patients with
acromegaly, but its duration of action is two weeks at
most.73 
CONCLUSIONS
The clinical introduction of somatostatin analogues
has resulted in new insights into the physiology of a
number of organ systems. Despite the broad range of
Figure 3. Serum Growth Hormone and Plasma Octreotide Con-
centrations in a Patient with Acromegaly Treated with a Long-
Acting Formulation of Octreotide.
The upper panel shows the effect of the intramuscular depot ad-
ministration of 30 mg of octreotide on mean serum growth hor-
mone concentrations. Each point represents the mean concen-
tration in eight blood samples, collected every hour between
8 a.m. and 4 p.m. on the day indicated. The arrows indicate the
injections. The control of growth hormone secretion was im-
proved after an increase in the frequency of injections to once
a month (starting with the third injection).
The lower panel shows the plasma octreotide concentrations be-
tween 8 a.m. and 4 p.m. on day 60 after the first injection ()
and on day 148, 28 days after the third injection (). The plasma
octreotide concentrations after 100 mg of octreotide had been
administered subcutaneously at 8:15 a.m., before the start of the
intramuscular depot injections, are also shown (O). (The plasma
octreotide values were determined by Dr. I. Lancranjan.72)
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physiologic actions of somatostatin, its analogues con-
trol hormonal hypersecretion by somatostatin-recep-
tor–positive endocrine tumors without serious side ef-
fects. The subtypes of somatostatin receptors on these
tumors may turn over at a different rate from those on
normal tissue. Therefore, the inhibitory effects of octre-
otide on hormonal hypersecretion by endocrine tumors
persist, whereas adaptation occurs in most normal so-
matostatin target tissues, thus preventing serious side
effects. These considerations form the basis for the list
of established, probable, and unestablished indications
for the use of somatostatin analogues (Table 2). Octre-
otide represents an important advance in the medical
management of pituitary adenomas secreting growth
hormone or thyrotropin, as well as in the treatment of
carcinoid tumors and inoperable islet-cell carcinomas
secreting vasoactive intestinal polypeptide or glucagon.
Treatment with octreotide offers a substantial improve-
ment in the quality of life among patients with these
diseases.
All functions of the gastrointestinal tract and the
exocrine pancreas are regulated by a multitude of lo-
cal factors, including a variety of peptide hormones.74
Pharmacologic amounts of somatostatin analogues ini-
tially inhibit a number of regulatory functions, but this
response is followed by local adaptation. On the one
hand, this adaptation is fortunate, because long-term
therapy usually causes only transient side effects. On
the other hand, local adaptation precludes a persistent
benefit of somatostatin and its analogues in the long-
term treatment of patients with functional abnormali-
ties of the gastrointestinal tract and the pancreas. This
adaptation to the inhibitory effects of octreotide has
been well documented in studies in normal subjects.75,76
After seven days of treatment with octreotide (100 to
300 mg per day), the initial inhibitory effects on the se-
cretion of gastric acid, amylase, trypsin, and lipase di-
minish or disappear. Nevertheless, short-term therapy
with octreotide is beneficial in patients undergoing elec-
tive pancreatic surgery and in those with variceal bleed-
ing, intestinal fistulas, or secretory diarrhea (Table 2).
More knowledge about the subtypes of somatostatin
receptors that account for the antimitotic actions of so-
matostatin, studies of the expression of these receptor
subtypes in different tumors, and the development of
subtype-specific somatostatin analogues may eventual-
ly result in new palliative treatments for patients with a
variety of tumors.
The benefits of treatment with somatostatin ana-
logues must always be weighed against the risk of ad-
verse effects associated with long-term treatment —
notably, the development of gallstones. The high cost of
treatment should also be considered. The recent devel-
opment of a long-acting depot preparation of octreotide
should make therapy much easier, and further improve-
ment in analogue formulations and the specificity of
their action can be anticipated.
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